Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 30,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, March 16th, Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30.

Mirum Pharmaceuticals Stock Down 4.3%

NASDAQ MIRM traded down $4.16 during trading hours on Tuesday, reaching $92.17. 661,237 shares of the company’s stock were exchanged, compared to its average volume of 1,225,544. The company’s 50-day moving average is $97.01 and its two-hundred day moving average is $89.76. Mirum Pharmaceuticals, Inc. has a one year low of $43.50 and a one year high of $114.99. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The company has a market capitalization of $5.62 billion, a price-to-earnings ratio of -6.77 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. During the same period last year, the company posted ($0.30) earnings per share. The business’s revenue was up 43.3% compared to the same quarter last year. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. MCF Advisors LLC grew its position in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals in the third quarter valued at about $33,000.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MIRM shares. Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Raymond James Financial reissued a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. TD Cowen lifted their target price on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price for the company. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $137.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.